ClinicalTrials.Veeva

Menu
M

Mid Atlantic Retina Specialists | Hagerstown, MD

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Aflibercept
APL-2
EYE201
MK-8748
Bevacizumab
ANX007
Axitinib
Sunitinib Malate
EYP-1901
BI 771716

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 17 total trials

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Active, not recruiting
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).Available standard (usual) treatments for NVAMD, s...

Enrolling
Choroidal Neovascularization
Age-Related Macular Degeneration
Drug: Tiespectus
Drug: Aflibercept

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on parti...

Active, not recruiting
Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema
Drug: Aflibercept 8 mg

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.

Active, not recruiting
Geographic Atrophy
Drug: Vonaprument
Other: Sham Administration

This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine ca...

Active, not recruiting
Macular Degeneration, Age-related
Geographic Atrophy
Drug: Pegcetacoplan
Drug: Sham comparator to BI 771716

ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of ne...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Genetic: ABBV-RGX-314 Dose 1
Biological: Aflibercept (EYLEA®)

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration

Active, not recruiting
Neovascular Age-related Macular Degeneration
Drug: OTX-TKI
Drug: Aflibercept

Trial sponsors

Jaeb Center for Health Research logo
A
Bayer logo
AbbVie logo
A
Boehringer Ingelheim logo
C
E
E
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems